Claritev (NYSE:CTEV) EVP Michael Kim Acquires 15,000 Shares

Key Points

• EVP Michael Kim bought 15,000 Claritev shares on March 12 at $16.50 (≈$247,500) and had earlier bought 30,000 shares on Feb 27 at $14.30, bringing his holdings to 182,878 shares (≈$3.02M) and increasing his stake by 8.94%.
• Shares recently traded at $18.53—well below the 50‑day ($23.93) and 200‑day ($42.93) moving averages—Claritev has a market cap of about $306M, institutional ownership of 87.15%, and a consensus analyst rating of Hold with an average target of $29.67.

Claritev (NYSE:CTEV - Get Free Report) EVP Michael Kim purchased 15,000 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was acquired at an average price of $16.50 per share, for a total transaction of $247,500.00. Following the purchase, the executive vice president owned 182,878 shares in the company, valued at approximately $3,017,487. The trade was a 8.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Kim also recently made the following trade(s):

• On Friday, February 27th, Michael Kim purchased 30,000 shares of Claritev stock. The shares were acquired at an average cost of $14.30 per share, with a total value of $429,000.00.

Claritev Price Performance

Shares of CTEV stock traded up $1.64 on Monday, hitting $18.53. 21,815 shares of the company's stock were exchanged, compared to its average volume of 226,946. The company has a 50 day moving average of $23.93 and a 200 day moving average of $42.93. The stock has a market cap of $305.93 million, a P/E ratio of -1.07 and a beta of 0.61. Claritev has a 12 month low of $12.04 and a 12 month high of $74.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers acquired a new stake in Claritev in the third quarter worth $567,000. JPMorgan Chase & Co. bought a new position in shares of Claritev during the 3rd quarter worth about $1,245,000. Vanguard Group Inc. bought a new position in shares of Claritev during the 3rd quarter worth about $27,483,000. Citigroup Inc. acquired a new stake in shares of Claritev in the 3rd quarter valued at about $2,025,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Claritev in the 3rd quarter valued at about $42,000. 87.15% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Claritev in a report on Monday, December 29th. Wells Fargo & Company set a $30.00 price target on Claritev and gave the stock an "equal weight" rating in a report on Tuesday, February 24th. UBS Group reaffirmed a "buy" rating on shares of Claritev in a report on Tuesday, February 24th. Guggenheim reaffirmed a "buy" rating on shares of Claritev in a research note on Tuesday, February 24th. Finally, Citigroup dropped their price objective on Claritev from $63.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $29.67.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.